ClinicalTrials.gg
CompletedNCT02603120Updated Nov 12, 2020Results posted

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

A Phase 3 interventional study of ABC/DTG/3TC and B/F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 94 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-12.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
567
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) to a FDC of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed Human Immunodeficiency Virus- 1 (HIV-1) infected adults.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Estimated ≥ 50 mL/min (≥ 0.83 mL/sec).
  • Currently receiving an antiretroviral regimen of DTG + ABC/3TC, or ABC/DTG/3TC FDC for ≥ 3 months prior to the screening visit.
  • ribonucleic acid (RNA) \< 50 copies/mL at the screening visit.
  • Currently on a stable regimen for ≥ 3 months preceding the screening visit with documented plasma HIV-1 RNA \< 50 copies/mL for ≥ 3 months preceding the screening visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
  • Have no documented or suspected resistance to emtricitabine (FTC), tenofovir (TFV), DTG, ABC or 3TC.

Key Exclusion Criteria:

  • Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance.
  • Active tuberculosis infection.
  • Individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding).
  • Females who are pregnant.
  • Females who are breastfeeding.
  • Acute hepatitis in the 30 days prior to study entry.
  • Chronic Virus (HBV) infection.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
567 participants (actual)

Study arms

  • Experimental
    Blinded Phase: B/F/TAF

    B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks

    Drug: B/F/TAF · Drug: ABC/DTG/3TC Placebo

  • Active comparator
    Blinded Phase: ABC/DTG/3TC

    ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks

    Drug: ABC/DTG/3TC · Drug: B/F/TAF Placebo

  • Experimental
    Open-Label Phase

    At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.

    Drug: B/F/TAF

Interventions

  • DrugABC/DTG/3TC

    600/50/300 mg FDC tablets administered orally once daily without regard to food

    Also known as: Triumeq®

  • DrugB/F/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    50/200/25 mg FDC tablets administered orally once daily without regard to food

    Also known as: Bictegravir (previously referred to as GS-9883)/Emtricitabine/Tenofovir Alafenamide, Biktarvy® [BVY]

  • DrugABC/DTG/3TC Placebo

    Tablets administered orally once daily without regard to food

  • DrugB/F/TAF Placebo

    Tablets administered orally once daily without regard to food

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Defined by the US FDA-defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  2. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48

  3. Spine Bone Mineral Density (BMD) at Baseline

    Time frame: Baseline

  4. Percentage Change From Baseline in Spine BMD at Week 48

    Time frame: Baseline; Week 48

  5. Hip Bone Mineral Density at Baseline

    Time frame: Baseline

  6. Percentage Change From Baseline in Hip BMD at Week 48

    Time frame: Baseline; Week 48

07

Results

Posted Jul 23, 2018

Participant flow

Participants were enrolled at study sites in North America, Europe, and Australia. The first participant was screened on 11 November 2015. The last study visit occurred on 23 October 2019.

Double-Blind Treatment Phase
Participant flow — Double-Blind Treatment Phase
MilestoneB/F/TAFABC/DTG/3TC
Started284283
Completed265267
Not completed1916
Withdrew: Withdrew consent48
Withdrew: Adverse event33
Withdrew: Lost to follow-up42
Withdrew: Death20
Withdrew: Investigator's discretion20
Withdrew: Pregnancy11
Withdrew: Non-compliance with study drug10
Withdrew: Did not receive study drug22
OL Extension B/F/TAF Treatment Phase
Participant flow — OL Extension B/F/TAF Treatment Phase
MilestoneB/F/TAFABC/DTG/3TC
Started259265
Completed254254
Not completed511
Withdrew: Lost to follow-up34
Withdrew: Investigator's discretion12
Withdrew: Withdrew consent12
Withdrew: Adverse event01
Withdrew: Death01
Withdrew: Lack of efficacy01

Outcome measures

PrimaryPercentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm
percentage of participantsB/F/TAFABC/DTG/3TC
Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm1.10.4
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · Difference in percentages: 0.7 · 95.002% CI -1.0 to 2.8The differences in percentages of participants between treatment groups and their 95.002% CIs were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
  • B/F/TAF vs ABC/DTG/3TC · Fisher Exact · p = 0.62
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL as Defined by the US FDA-defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Defined by the US FDA-defined Snapshot Algorithm
percentage of participantsB/F/TAFABC/DTG/3TC
Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Defined by the US FDA-defined Snapshot Algorithm93.695.0
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · Difference in percentages: -1.4 · 95.002% CI -5.5 to 2.6The differences in percentages of participants between treatment groups and their 95.002% CIs were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
  • B/F/TAF vs ABC/DTG/3TC · Fisher Exact · p = .59
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 48
cells/µLB/F/TAFABC/DTG/3TC
Change From Baseline in CD4+ Cell Count at Week 48-31 ± 181.34 ± 191.0
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.031 · Difference in least squares means: -35 · 95% CI -67 to -3
SecondarySpine Bone Mineral Density (BMD) at Baseline
Time frame:
Baseline
Reported as:
Mean · g/cm^2
Spine Bone Mineral Density (BMD) at Baseline
g/cm^2B/F/TAFABC/DTG/3TC
Spine Bone Mineral Density (BMD) at Baseline1.124 ± 0.18331.103 ± 0.1548
SecondaryPercentage Change From Baseline in Spine BMD at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · percentage change
Percentage Change From Baseline in Spine BMD at Week 48
percentage changeB/F/TAFABC/DTG/3TC
Percentage Change From Baseline in Spine BMD at Week 480.692 ± 3.12960.416 ± 2.9973
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.33 · Difference in least squares means: 0.276 · 95% CI -0.275 to 0.827
SecondaryHip Bone Mineral Density at Baseline
Time frame:
Baseline
Reported as:
Mean · g/cm^2
Hip Bone Mineral Density at Baseline
g/cm^2B/F/TAFABC/DTG/3TC
Hip Bone Mineral Density at Baseline1.006 ± 0.14710.996 ± 0.1363
SecondaryPercentage Change From Baseline in Hip BMD at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · percentage change
Percentage Change From Baseline in Hip BMD at Week 48
percentage changeB/F/TAFABC/DTG/3TC
Percentage Change From Baseline in Hip BMD at Week 480.156 ± 2.21380.299 ± 2.1077
Statistical analysis
  • B/F/TAF vs ABC/DTG/3TC · ANOVA · p = 0.47 · Difference in least squares means: -0.143 · 95% CI -0.534 to 0.248

Adverse events

Collected over First dose date up to 169 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind: B/F/TAF2/282 (0.7%)17/282 (6%)122/282 (43.3%)
Double-Blind: ABC/DTG/3TC0/281 (0%)26/281 (9.3%)132/281 (47%)
Open-label Extension: B/F/TAF From B/F/TAF1/259 (0.4%)24/259 (9.3%)84/259 (32.4%)
Open-label Extension: B/F/TAF From ABC/DTG/3TC1/265 (0.4%)11/265 (4.2%)82/265 (30.9%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventDouble-Blind: B/F/TAFDouble-Blind: ABC/DTG/3TCOpen-label Extension: B/F/TAF From B/F/TAFOpen-label Extension: B/F/TAF From ABC/DTG/3TC
Atrial fibrillationCardiac disorders0/2822/2810/2590/265
Abscess limbInfections and infestations0/2822/2810/2591/265
Intentional overdoseInjury, poisoning and procedural complications2/2820/2810/2590/265
OverdoseInjury, poisoning and procedural complications2/2820/2810/2590/265
Suicidal ideationPsychiatric disorders2/2821/2810/2590/265
Suicide attemptPsychiatric disorders2/2820/2810/2590/265
Acute myocardial infarctionCardiac disorders1/2820/2811/2590/265
Abdominal painGastrointestinal disorders0/2820/2811/2590/265
DiarrhoeaGastrointestinal disorders0/2820/2811/2590/265
Duodenal ulcerGastrointestinal disorders0/2820/2811/2590/265
Most frequent other events
Most frequent other events
EventDouble-Blind: B/F/TAFDouble-Blind: ABC/DTG/3TCOpen-label Extension: B/F/TAF From B/F/TAFOpen-label Extension: B/F/TAF From ABC/DTG/3TC
Upper respiratory tract infectionInfections and infestations34/28232/28122/25926/265
DiarrhoeaGastrointestinal disorders26/28218/28120/25911/265
NasopharyngitisInfections and infestations21/28222/28120/25922/265
HeadacheNervous system disorders19/28223/2815/2599/265
InsomniaPsychiatric disorders9/28222/2811/2597/265
ArthralgiaMusculoskeletal and connective tissue disorders21/28218/2818/2596/265
NauseaGastrointestinal disorders6/28216/2813/2591/265
BronchitisInfections and infestations11/28215/28111/2598/265
SinusitisInfections and infestations11/28215/2819/25913/265
Back painMusculoskeletal and connective tissue disorders13/28213/28113/2596/265

Baseline characteristics

The Safety Analysis Set included participants who were randomized into the study and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)B/F/TAFABC/DTG/3TCTotal
Mean46 ± 11.145 ± 11.545 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)B/F/TAFABC/DTG/3TCTotal
Female352964
Male247252499
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAFABC/DTG/3TCTotal
American Indian or Alaska Native224
Asian9918
Black5962121
Native Hawaiian or Pacific Islander303
White206202408
Other336
Not Permitted033
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAFABC/DTG/3TCTotal
Hispanic or Latino465298
Not Hispanic or Latino236227463
Not Permitted022
Region of Enrollment
Region of Enrollment(Participants)B/F/TAFABC/DTG/3TCTotal
Canada132235
Belgium112
United States203198401
Italy112
United Kingdom336
France4812
Germany171128
Spain313162
Australia9615
HIV-1 RNA Categories
HIV-1 RNA Categories(Participants)B/F/TAFABC/DTG/3TCTotal
< 50 copies/mL278272550
≥ 50 copies/mL4913
CD4 Cell Count
CD4 Cell Count(cell/µL)B/F/TAFABC/DTG/3TCTotal
Mean752 ± 302.2694 ± 291.6723 ± 298.1
CD4 Cell Count Category
CD4 Cell Count Category(Participants)B/F/TAFABC/DTG/3TCTotal
≥ 50 to < 200 cells/μL6410
≥ 200 to < 350 cells/μL163046
≥ 350 to < 500 cells/μL334275
≥ 500 cells/μL227205432
08

Study locations

94 sites
  • Phoenix, Arizona 85012, United States
  • Beverly Hills, California 90211, United States
  • Los Angeles, California 90027, United States
  • Los Angeles, California 90033, United States
  • Los Angeles, California 90036, United States
  • Los Angeles, California 90069, United States
  • Oakland, California 94602, United States
  • Oakland, California 94609, United States
  • Palm Springs, California 92264, United States
  • Sacramento, California 95187, United States
  • Sacramento, California 95825, United States
  • San Leandro, California 94577, United States
  • Washington, District of Columbia 20009, United States
  • Washington, District of Columbia 20036, United States
  • DeLand, Florida 32720, United States
  • Fort Lauderdale, Florida 33308, United States
  • Fort Lauderdale, Florida 33316, United States
  • Fort Pierce, Florida 34982, United States
  • Miami Beach, Florida 33139, United States
  • Miami, Florida 33133, United States
  • Orlando, Florida 32803, United States
  • Pensacola, Florida 32504, United States
  • Tampa, Florida 33614, United States
  • Vero Beach, Florida 32960, United States
  • West Palm Beach, Florida 33401, United States
  • Wilton Manors, Florida 33305, United States
  • Augusta, Georgia 30912, United States
  • Decatur, Georgia 30033, United States
  • Macon, Georgia 31201, United States
  • Savannah, Georgia 31401, United States
  • Honolulu, Hawaii 96813, United States
  • Chicago, Illinois 60613, United States
  • Chicago, Illinois 60657, United States
  • Louisville, Kentucky 40202, United States
  • New Orleans, Louisiana 70112, United States
  • Boston, Massachusetts 02118-2393, United States
  • Springfield, Massachusetts 01105, United States
  • Berkley, Michigan 48072, United States
  • Detroit, Michigan 48202, United States
  • Minneapolis, Minnesota 55415, United States
  • Kansas City, Missouri 64111, United States
  • Saint Louis, Missouri 63139, United States
  • Newark, New Jersey 07102, United States
  • Santa Fe, New Mexico 87505, United States
  • Bronx, New York 10467-2490, United States
  • Buffalo, New York 14215, United States
  • New York, New York 10011, United States
  • Charlotte, North Carolina 28207, United States
  • Greenville, North Carolina 27834, United States
  • Huntersville, North Carolina 28078, United States
  • Cincinnati, Ohio 45267-0560, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Columbia, South Carolina 29203-6840, United States
  • Austin, Texas 78705, United States
  • Dallas, Texas 75219, United States
  • Dallas, Texas 75246, United States
  • Houston, Texas 77004, United States
  • Houston, Texas 77098, United States
  • Longview, Texas 75605, United States
  • Seattle, Washington 98104, United States
  • Spokane, Washington 99204, United States
  • Sydney, New South Wales 2010 NSW, Australia
  • Sydney, New South Wales 2010, Australia
  • Ghent, 9000, Belgium
  • Vancouver, British Columbia V6Z 2T1, Canada
  • Winnipeg, Manitoba R3A 1R9, Canada
  • Montreal, Quebec H2L 4P9, Canada
  • Montreal, Quebec H3A 1T1, Canada
  • Montreal, Quebec H4A 3J1, Canada
  • Nantes, 44093, France
  • NICE Cedex 03, 6202, France
  • Paris cedex 20, 75970, France
  • Paris, 75010, France
  • Berlin, 12157, Germany
  • Berlin, 13353, Germany
  • Bonn, 53127, Germany
  • Essen, 45122, Germany
  • Frankfurt am Main, 60596, Germany
  • Hamburg, 20146, Germany
  • Munich, 80336, Germany
  • München, 80335, Germany
  • Roma, 00149, Italy
  • San Juan, 00909-1711, Puerto Rico
  • San Juan, 00909, Puerto Rico
  • Badalona, 08916, Spain
  • Badalona, 8907, Spain
  • Barcelona, 8025, Spain
  • Cordoba, 14004, Spain
  • Madrid, 28034, Spain
  • Santiago de Compostela, 15706, Spain
  • Sevilla, 41013, Spain
  • Brighton, BN2 3EW, United Kingdom
  • Manchester, M13 0FH, United Kingdom
  • Manchester, M8 5RB, United Kingdom
09

References and documents

Publications

  • Andreatta K, Willkom M, Martin R, Chang S, Wei L, Liu H, Liu YP, Graham H, Quirk E, Martin H, White KL. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. J Antimicrob Chemother. 2019 Dec 1;74(12):3555-3564. doi: 10.1093/jac/dkz347. Erratum In: J Antimicrob Chemother. 2019 Dec 1;74(12):3646-3647. doi: 10.1093/jac/dkz412. PubMed 31430369 ↗
  • Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, Lopez-Cortes L, Ruane P, Podzamczer D, Brinson C, Custodio J, Liu H, Andreatta K, Martin H, Cheng A, Quirk E. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018 Jul;5(7):e357-e365. doi: 10.1016/S2352-3018(18)30092-4. Epub 2018 Jun 18. Erratum In: Lancet HIV. 2018 Oct;5(10):e545. doi: 10.1016/S2352-3018(18)30147-4. PubMed 29925489 ↗
  • Wohl D, Clarke A, Maggiolo F, Garner W, Laouri M, Martin H, Quirk E. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 2018 Oct;11(5):561-573. doi: 10.1007/s40271-018-0322-8. PubMed 29956087 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in May 2017, 17 months.

Results were first posted in Jul 2018, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2015
First posted
Nov 11, 2015
StartActual
Nov 11, 2015
Primary completionActual
May 9, 2017
CompletionActual
Oct 23, 2019
Results first posted
Jul 23, 2018
Last update
Nov 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02603120
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 11, 2015
Start date
Nov 11, 2015
Primary completion
May 9, 2017
Completion
Oct 23, 2019
Results posted
Jul 23, 2018
Last update
Nov 12, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion